Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 5/20 | 0.52 |
| ▸ | CCR2 | P41597 | 9/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.49 |
| ▸ | YAP1 | P46937 | 1/20 | 0.48 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.48 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3870138 | 1.00 | RXFP1 (0.52) | RXFP1CCR2KCNH2YAP1TEAD4 | |
| SCHEMBL3871377 | 1.00 | RXFP1 (0.52) | RXFP1CCR2KCNH2YAP1TEAD4 | |
| SCHEMBL3872474 | 0.92 | RXFP1 (0.50) | RXFP1CCR2YAP1TEAD4TEAD2 | |
| SCHEMBL3872477 | 0.92 | RXFP1 (0.50) | RXFP1CCR2YAP1TEAD4TEAD2 | |
| SCHEMBL3879505 | 0.88 | MT-CO2 (0.44) | HTTL3MBTL1 | |
| SCHEMBL3879507 | 0.88 | MT-CO2 (0.44) | HTTL3MBTL1 | |
| SCHEMBL13853135 | 0.87 | RXFP1 (0.48) | RXFP1CCR2KCNH2YAP1TEAD4 | |
| SCHEMBL13853136 | 0.87 | RXFP1 (0.48) | RXFP1CCR2KCNH2YAP1TEAD4 | |
| SCHEMBL3873813 | 0.87 | RXFP1 (0.56) | RXFP1CCR2KCNH2YAP1TEAD4 | |
| SCHEMBL3879506 | 0.87 | RXFP1 (0.56) | RXFP1CCR2KCNH2YAP1TEAD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891064-B1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | ALMIRALL SA (ES) | 2009-09-02 | — | — | EP | disclosed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | disclosed |
| EP-1891064-A1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | Laboratorios Almirall, S.A. (ES) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006133802-A1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | CCR1, CCR3, CCR8 | RXFP1 347/4885CCR2 6/4885KCNH2 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.